Introduction
Inflammatory bowel disease (IBD), comprising Crohn’s disease and ulcerative colitis, is characterised by chronic intestinal inflammation with periods of active disease and remission. Although symptom control is an important treatment goal, clinical improvement does not always indicate that intestinal inflammation has resolved. Integrating symptom assessment with objective measures of disease activity can help healthcare professionals evaluate treatment response and guide long-term management.[1,2]
Why Is Objective Monitoring Important?
Persistent inflammation despite symptomatic improvement may contribute to ongoing tissue damage and disease complications. Conversely, symptoms such as abdominal pain and diarrhoea may persist even when inflammatory activity is limited, requiring clinicians to consider other potential causes.
A treat-to-target approach incorporates predefined treatment goals and regular reassessment to determine whether these goals have been achieved. The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE-II) consensus highlights clinical remission and endoscopic healing as important long-term treatment targets.[2]
Key Considerations for Clinical Practice
1. Assess clinical symptoms and patient-reported outcomes
Evaluate stool frequency, rectal bleeding, abdominal pain, fatigue and their impact on daily functioning. Symptom assessment provides essential clinical context but should not be used as the sole indicator of inflammatory activity.
2. Incorporate objective biomarkers
Faecal calprotectin is a useful non-invasive marker of intestinal inflammation, while C-reactive protein (CRP) can help assess systemic inflammation. Results should be interpreted alongside clinical findings, as biomarker performance may vary according to disease location and individual patient characteristics.[1,2]
3. Use endoscopy and imaging when indicated
Endoscopic assessment can help evaluate mucosal healing and ongoing inflammation. Intestinal ultrasound and magnetic resonance enterography may provide additional information, particularly in Crohn’s disease, where inflammation can affect deeper bowel layers or involve segments that are not readily assessed by conventional endoscopy.[1]
4. Individualise monitoring and treatment decisions
The frequency and choice of monitoring investigations should reflect disease phenotype, treatment changes, previous findings and clinical risk. Reassessment can help identify inadequate treatment response and support timely adjustments in management, in accordance with relevant clinical guidelines.[1,2]
Conclusion
Effective IBD management extends beyond the relief of gastrointestinal symptoms. Combining clinical assessment with biomarkers, endoscopy and appropriate imaging provides a more comprehensive understanding of disease activity and supports informed, individualised treatment decisions.
Clinical takeaway: Symptom improvement is important, but objective assessment remains essential for evaluating inflammatory control and monitoring treatment targets.
References
Kucharzik T, et al. ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 1. Journal of Crohn's and Colitis. 2025;19(7). https://doi.org/10.1093/ecco-jcc/jjaf106
Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease Initiative of the International Organization for the Study of IBD. Gastroenterology. 2021;160(5):1570–1583. https://doi.org/10.1053/j.gastro.2020.12.031
Disclaimer: This article is intended for healthcare professional education and does not replace clinical judgement or locally applicable guidelines.